

## CLINICAL CANCER RESEARCH

## TABLE OF CONTENTS

## HIGHLIGHTS

2081 Selected Articles from This Issue

## SPECIAL FEATURES

## CCR Translations

2083 "Liquid Gold" - The unTAPped Potential of Cerebrospinal Fluid Analysis?  
Isabella C. Glitza Oliva and Hussein A. Tawbi  
See related article, p. 2163

2085 TNF $\alpha$  Blockade in Checkpoint Inhibition: The Good, the Bad, or the Ugly?  
Jeffrey S. Weber and Michael A. Postow  
See related article, p. 2268

## Review

2087 Targeting PD-1 or PD-L1 in Metastatic Kidney Cancer: Combination Therapy in the First-Line Setting  
David H. Aggen, Charles G. Drake, and Brian I. Rini

## CLINICAL TRIALS: TARGETED THERAPY

2096 Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study  
Matthew S. Davids, Bryone J. Kuss, Peter Hillmen, Marco Montillo, Carol Moreno, James Essell, Nicole Lamanna, Zsolt Nagy, Constantine S. Tam, Stephan Stilgenbauer, Paolo Ghia, Julio Delgado, Stephanie Lustgarten, David T. Weaver, Hagop Youssoufian, and Ulrich Jäger

2104 Prospective Evaluation of Bone Metabolic Markers as Surrogate Markers of Response to Radium-223 Therapy in Metastatic Castration-resistant Prostate Cancer  
Neeraj Agarwal, Roberto Nussenzeveig, Andrew W. Hahn, John M. Hoffman, Kathryn Morton, Sumati Gupta, Julia Batten, Jared Thorley, Josiah Hawks, Victor Sacristan Santos, Gayatri Nachaegari, Xuechen Wang, Kenneth Boucher, Benjamin Haaland, and Benjamin L. Maughan

2111 TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR<sup>+</sup> Metastatic Triple-Negative Breast Cancer  
Brian D. Lehmann, Vandana G. Abramson, Melinda E. Sanders, Erica L. Mayer, Tufia C. Haddad, Rita Nanda, Catherine Van Poznak, Anna Maria Storniolo, Julie R. Nangia, Paula I. Gonzalez-Ericsson, Violeta Sanchez, Kimberly N. Johnson, Richard G. Abramson, Sheau-Chiann Chen, Yu Shyr, Carlos L. Arteaga, Antonio C. Wolff, Jennifer A. Pietenpol, and the Translational Breast Cancer Research Consortium

## CLINICAL TRIALS: IMMUNOTHERAPY

2124 Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study  
Jonathan Strosberg, Nobumasa Mizuno, Toshihiko Doi, Enrique Grande, Jean-Pierre Delord, Ronnie Shapira-Frommer, Emily Bergsland, Manisha Shah, Marwan Fakhri, Shunji Takahashi, Sarina A. Piha-Paul, Bert O'Neil, Sajeve Thomas, Martijn P. Lolkema, Menghui Chen, Nageatte Ibrahim, Kevin Norwood, and Julien Hadoux

## PRECISION MEDICINE AND IMAGING

2131 Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TRENd Trial  
Amelia McCartney, Martina Bonechi, Francesca De Luca, Chiara Biagioni, Giuseppe Curigliano, Erica Moretti, Alessandro Marco Minisini, Mattias Bergqvist, Matteo Benelli, Ilenia Migliaccio, Francesca Galardi, Emanuela Risi, Irene De Santo, Dario Romagnoli, Laura Biganzoli, Angelo Di Leo, and Luca Malorni

2140 Efficacy of Affibody-Based Ultrasound Molecular Imaging of Vascular B7-H3 for Breast Cancer Detection  
Rakesh Bam, Patrick S. Lown, Lawrence A. Stern, Karina Sharma, Katheryne E. Wilson, Gregory R. Bean, Amelie M. Lutz, Ramasamy Paulmurugan, Benjamin J. Hackel, Jeremy Dahl, and Lotfi Abou-Elkacem

# TABLE OF CONTENTS

- 2151 Identification of Non–Small Cell Lung Cancer Sensitive to Systemic Cancer Therapies Using Radiomics**  
Laurent Derclé, Matthew Fronheiser, Lin Lu, Shuyan Du, Wendy Hayes, David K. Leung, Amit Roy, Julia Wilkerson, Pingzhen Guo, Antonio T. Fojo, Lawrence H. Schwartz, and Binsheng Zhao
- 2163 Proteomic Analysis of CSF from Patients with Leptomeningeal Melanoma Metastases Identifies Signatures Associated with Disease Progression and Therapeutic Resistance**  
Inna Smalley, Vincent Law, Clayton Wyatt, Brittany Evernden, Bin Fang, John M. Koomen, Eric A. Welsh, Robert J.B. Macaulay, Peter A. Forsyth, and Keiran S.M. Smalley  
See related commentary, p. 2083
- 2176 Adenosine Signaling Is Prognostic for Cancer Outcome and Has Predictive Utility for Immunotherapeutic Response**  
Ben Sidders, Pei Zhang, Kelly Goodwin, Greg O'Connor, Deanna L. Russell, Alexandra Borodovsky, Joshua Armenia, Robert McEwen, Bolan Linghu, Johanna C. Bendell, Todd M. Bauer, Manish R. Patel, Gerald S. Falchook, Melinda Merchant, Gayle Pouliot, J. Carl Barrett, Jonathan R. Dry, Rich Woessner, and Kris Sachsenmeier
- 2188 A Novel GUCY2C-CD3 T-Cell Engaging Bispecific Construct (PF-07062119) for the Treatment of Gastrointestinal Cancers**  
**A C** Divya Mathur, Adam R. Root, Bozena Bugaj-Gaweda, Stephanie Bisulco, Xingzhi Tan, Wei Fang, Jessica C. Kearney, Justin Lucas, Magali Guffroy, Jonathan Golas, Cynthia M. Rohde, Chad Stevens, Cris Kamperschroer, Kerry Kelleher, Rosemary F. Lawrence-Henderson, Erik Upeslakis, Johnny Yao, Jatin Narula, Edward R. LaVallie, Diane R. Fernandez, Bernard S. Buetow, Edward Rosfjord, Laird Bloom, Lindsay E. King, Lioudmila Tchistiakova, Anhco Nguyen, and Puja Sapra
- 2203 Preclinical Activity of JNJ-7957, a Novel BCMA $\times$ CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab**  
Kristine A. Frerichs, Marloes E.C. Broekmans, Jhon A. Marin Soto, Berris van Kessel, Martijn W. Heymans, Lisa C. Holthof, Christie P.M. Verkleij, Rengasamy Boominathan, Bhavesh Vaidya, Jocelyn Sendecki, Amy Axel, Francois Gaudet, Kodandaram Pillarisetti, Sonja Zweegman, Homer C. Adams III, Tuna Mutis, and Niels W.C.J. van de Donk
- 2216 Synergistic Combination of Oncolytic Virotherapy and Immunotherapy for Glioma**  
Bingtao Tang, Zong Sheng Guo, David L. Bartlett, David Z. Yan, Claire P. Schane, Diana L. Thomas, Jia Liu, Grant McFadden, Joanna L. Shisler, and Edward J. Roy
- 2231 Surfactant Expression Defines an Inflamed Subtype of Lung Adenocarcinoma Brain Metastases that Correlates with Prolonged Survival**  
Kolja Pocha, Andreas Mock, Carmen Rapp, Steffen Dettling, Rolf Warta, Christoph Geisenberger, Christine Jungk, Leila R. Martins, Niels Grabe, David Reuss, Juergen Debus, Andreas von Deimling, Amir Abdollahi, Andreas Unterberg, and Christel C. Herold-Mende
- 2244 ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non–Small Cell Lung Cancer**  
Naoko Okura, Naoya Nishioka, Tadaaki Yamada, Hirokazu Taniguchi, Keiko Tanimura, Yuki Katayama, Akihiro Yoshimura, Satoshi Watanabe, Toshiaki Kikuchi, Shinsuke Shiotsu, Takeshi Kitazaki, Akihiro Nishiyama, Masahiro Iwasaku, Yoshiko Kaneko, Junji Uchino, Hisanori Uehara, Mano Horinaka, Toshiyuki Sakai, Kohei Tanaka, Ryohei Kozaki, Seiji Yano, and Koichi Takayama
- 2257 Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell Carcinoma**  
Ivelina Spassova, Selma Ugurel, Patrick Terheyden, Antje Sucker, Jessica C. Hassel, Cathrin Ritter, Linda Kubat, Daniel Habermann, Farnoush Farahpour, Mohammadkarim Saeedghalati, Lukas Peiffer, Rajiv Kumar, David Schrama, Daniel Hoffmann, Dirk Schadendorf, and Jürgen C. Becker
- 2268 Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1-Treated Patients in the Dutch Melanoma Treatment Registry**  
Rik J. Verheijden, Anne M. May, Christian U. Blank, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel, Alfonsus J.M. van den Eertwegh, Jan Willem B. de Groot, Marye J. Boers-Sonderen, Jacobus J.M. van der Hoeven, Geke A. Hospers, Djura Piersma, Rozemarijn S. van Rijn, Albert J. ten Tije, Astrid A.M. van der Veldt, Gerard Vreugdenhil, Michiel C.T. van Zeijl, Michel W.J.M. Wouters, John B.A.G. Haanen, Ellen Kapiteijn, and Karijn P.M. Suijkerbuijk  
See related commentary, p. 2085

# TABLE OF CONTENTS

## LETTERS TO THE EDITOR

- 2275 Plasma cfDNA in Glioblastoma—Letter**  
Takeshi Takayasu, Yoshua Esquenazi, and  
Leomar Y. Ballester
- 2276 Plasma cfDNA in Glioblastoma—Response**  
Stephen J. Bagley and Erica L. Carpenter


## CORRECTION

- 2277 Correction: EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas**  
Susan E. Jorge, Antonio R. Lucena-Araujo,  
Hiroyuki Yasuda, Zofia Piotrowska,  
Geoffrey R. Oxnard, Deepa Rangachari,  
Mark S. Huberman, Lecia V. Sequist,  
Susumu S. Kobayashi, and Daniel B. Costa

**AC** AC icon indicates AuthorChoice  
For more information please visit [www.aacrjournals.org](http://www.aacrjournals.org)

## ABOUT THE COVER

This cover shows a hematoxylin- and eosin-stained section from a human breast carcinoma tissue. Corresponding immunohistochemical staining showed a highly specific expression of B7-H3 in tumor epithelial and endothelial compartments compared with the surrounding normal tissue. This illustration supports the utility of molecular imaging tools in clinical practice for noninvasive diagnosis of breast cancer. For details, see the article by Bam and colleagues on page 2140 of this issue.



# Clinical Cancer Research

**26 (9)**

*Clin Cancer Res* 2020;26:2081-2277.

**Updated version** Access the most recent version of this article at:  
<http://clincancerres.aacrjournals.org/content/26/9>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/26/9>.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.